Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU5E-9P refers to a specific pseudogene within the small nuclear RNA U5 family. U5 snRNAs are essential components of the spliceosome complex that catalyzes pre-mRNA splicing in eukaryotic cells[1][3]. However, the "-P" suffix designates RNU5E-9P as a pseudogene—an unexpressed or non-functional variant. Most snRNA pseudogenes in the human genome are not transcribed and do not have protein or RNA products[2]. There is currently no evidence that RNU5E-9P has biological activity, disease relevance, or drug interactions, and it is not considered a therapeutic target[4]. The broader U5 snRNA class (excluding pseudogenes) is vital for exon alignment during splicing but the pseudogene form does not participate in this process[1]. If you require information on active U5 snRNA genes (such as RNU5A-1 or RNU5B-1), which have a confirmed molecular role and disease associations, please specify. RNU5E-9P, as a pseudogene, does not have those characteristics[1].
None (no known mechanism; not a target for drugs or biomolecular intervention)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U5E small nuclear 9, pseudogene (RNU5E-9P).